期刊文献+

肝细胞癌中API-5水平升高与细胞凋亡减少

Increase of API-5 level and decrease of cell apoptosis in hepatocellular Carcinoma
下载PDF
导出
摘要 目的为了为揭示肝癌发生的分子机制提供线索,了解肝细胞癌中API-5表达与细胞凋亡之间的关系。方法手术取得并确诊肝细胞癌和癌旁组织各16例,通过免疫组织化学二步法检测凋亡抑制因子-5(apoptosis inhibitor-5,API-5)的表达,利用TUNEL法检测其细胞凋亡,API-5表达水平和细胞凋亡水平用IPP v5.1图像分析软件进行检测分析。结果在肝细胞癌组肝细胞中,API-5蛋白水平明显高于癌旁组织组,而细胞凋亡水平则明显低于癌旁组织组。结论肝细胞中高水平的API-5作为细胞凋亡抑制蛋白,抑制了细胞的凋亡,打破了其细胞增殖和凋亡之间的平衡,导致肝细胞癌发生。 Objective To provide a clue to reveal the molecular mechanism of liver carcinogenesis;to understand the relationship between API-5 expression and cell apoptosis in hepatocellular carcinoma(HCC).Methods HCC and carcinoma-adjacent tissues of 16 cases were obtained after surgery and diagnosis were confirmed by HE staining.API-5 protein expression of these tissues was detected by the two-step immunohistochemical method,and their apoptosis detected by TUNEL.IPP-v-5.1 image analysis software was used to detect and analyze API-5 expression and cell apoptosis.Results The expression level of API-5 protein in the HCC group was remarkably higher than that in the carcinoma-adjacent tissue group.The level of apoptosis in HCC was remarkably lower than that in carcinoma-adjacent tissue.Conclusion High expression of API-5,an apoptosis inhibiting protein,in liver cells may inhibit cell apoptosis,break the balance between cell proliferation and apoptosis,and thus induce hepatocellular carcinogenesis.
出处 《中国组织化学与细胞化学杂志》 CAS CSCD 2016年第1期67-69,共3页 Chinese Journal of Histochemistry and Cytochemistry
基金 烟台市科技计划课题(2011077)
关键词 肝细胞癌 凋亡抑制子-5 细胞凋亡 Hepatocellular carcinoma Apoptosis inhibitor-5 Apoptosis
  • 相关文献

参考文献4

二级参考文献31

  • 1邓敬桓,秦雪.原发性肝癌发生机制的研究进展[J].环境与健康杂志,2007,24(11):924-926. 被引量:14
  • 2Chang-suo LIU Yong CHENG Jin-feng HU Wei ZHANG Nai-hong CHEN Jun-tian ZHANG.Comparison of antioxidant activities between salvianolic acid B and Ginkgo biloba extract(EGb 761)[J].Acta Pharmacologica Sinica,2006,27(9):1137-1145. 被引量:17
  • 3单长民,李娟,李璞.肝癌的细胞凋亡和治疗[J].中国临床药理学与治疗学,2006,11(8):851-856. 被引量:4
  • 4[2]Shikata F,Tokumistu H,Ichikawa H,et al.In vitro cellular accumulation of gadolinium incorporated into chitosan nanoparticles designed for neutron-capture therapy of cancer.Eur J Pharm Biopharm,2002,53(1):57-63.
  • 5[3]Harisinghani MG,Barentsz J,Hahn PF,et al.Noninvasive detection of clinically occult lymph-node metastases in ptostate cancer.N Engl J Med,2003,348(25):2491-2499.
  • 6[4]Tamura T,Fujita F,Tanimoto M,et al.Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice.J Control Release,2002,80(1-3):295-307.
  • 7[5]Khandare J,Minko T.Polymer-drug conjugates:progress in polymeric prodrugs.Prog Polym Sci,2006,31(4):359-397.
  • 8[6]Moghimi SM,Hunter AC.Poloxamers and poloxamines in nanoparticle engineering and experimental medicine.Trends Biotechnol,2000,18(10):412-420.
  • 9[7]Maeda H.The enhanced permeability and retention (EPR) effect in tumor vasculature:the key role of tumor-selective macromolecular drug targeting.Adv Enzyme Regul,2001,41:189-207.
  • 10[8]David A,Kopecková P,Minko T,et al.Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.Eur J Cancer,2004,40(1):148-157.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部